Columbia Laboratories to be listed on NASDAQ Biotechnology Index

Download PDF Copy

May 17 2011

NewsGuard 100/100 Score

Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced the Company will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI). The semi-annual re-ranking of the index will become effective when the market opens on Monday May 23, 2011.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is re-ranked semi-annually in May and November, and serves as the basis for the iShares NASDAQ Biotechnology Index FundSM (IBB).

Source:

Columbia Laboratories

Posted in: Business / Finance

Tags: Biotechnology, Drug Delivery, New Drug Application, Pharmaceuticals, Pregnancy, Progesterone

Comments (0)

Download PDF Copy

Suggested Reading

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

UChicago scientists develop a new approach to study snoRNAs

UChicago scientists develop a new approach to study snoRNAs

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Solascure and U.S. Army Institute of Surgical Research collaborate for combat wound care

Solascure and U.S. Army Institute of Surgical Research collaborate for combat wound care

Engineered virus-like particles evolve for superior gene delivery efficiency

Engineered virus-like particles evolve for superior gene delivery efficiency

ProductLife Group (PLG) Acquires Halloran

ProductLife Group (PLG) Acquires Halloran

Greener And Cleaner: Yeast-Green Algae Mix Improves Water Treatment

Greener And Cleaner: Yeast-Green Algae Mix Improves Water Treatment

Targeted bacteriophages offer standardized and scalable GI therapy

Targeted bacteriophages offer standardized and scalable GI therapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Advancing vaccine development through green biotechnology